Board of Directors

Dr. Erich Hunziker

Chairman
read more

Dr. Erich Hunziker

Chairman
« BB Biotech is a strong growth play and it offers a high income stream on top of that »

Dr. Erich Hunziker has been on the Board of Directors of BB Biotech AG since 2011 and has been elected president in 2013. He previously served as CFO of Roche from 2001–2010. From 1983–2001 he held various executive positions at Corange, Boehringer Mannheim and, before joining Roche, at Diethelm-Keller-Gruppe, where he ultimately served as CEO. Erich Hunziker earned a PhD in Industrial Engineering from  the Swiss Federal Institute of Technology in Zurich. Dr. Erich Hunziker is Chairman of the Board of Directors of Light Chain Biosciences AG, NovImmune SA, Entsia International AG and discoveric ag. Furthermore he is a member of the Board of Directors of LamKap Bio alpha AG, LamKap Bio beta AG and LamKap Bio gamma AG.

Dr. Clive Meanwell

Vice Chairman
read more

Dr. Clive Meanwell

Vice Chairman
« More and more biotech firms are turning a profit. This trend should continue thanks to the full R&D pipelines »

Dr. Clive Meanwell is Vice Chairman of the Board of Directors of BB Biotech AG since 2003. He founded The Medicines Company in 1996 and from then until January 6, 2020 he was a Member of the BoD and held a range of leadership positions including Chairman, Executive Chairman, CEO and CIO. From 1995–1996, he was a founding partner and managing director of MPM Capital L.P. He previously held various positions at Hoffmann-La Roche in Basel and Palo Alto, California. Dr. Meanwell received his MD and PhD from the University of Birmingham in the UK where he also trained in medical oncology.

Dr. Susan Galbraith

Member
read more

Dr. Susan Galbraith

Member

Dr. Susan Galbraith has been on the Board of Directors of BB Biotech since 2020. She joined AstraZeneca in 2010 where she is Head of Oncology Research and Early Development. She oversaw the successful development of several cancer drugs that have been approved in countries around the world. She also co-leads the Cambridge Cancer Center Onco-Innovation Group. Susan Galbraith is also on the Board of Directors of Horizon Discovery PLD, a member of the Scientific advisory board of the ICR Cancer Research Center of Excellence and she sits on the AACR Finance Committee as well as the AACR 2020 Annual Meeting Scientific Program Committee. 

Prof. Dr. Mads Krogsgaard Thomsen

Member
read more

Prof. Dr. Mads Krogsgaard Thomsen

Member

Mads Krogsgaard Thomsen has been on the Board of Directors of BB Biotech since 2020. He has been with Novo Nordisk since 1991. He has held several executive roles in the company’s growth hormone and diabetes research operations, and currently serves as Executive Vice President, Head of R&D and Chief Science Officer. Professor Thomsen has chaired Danish Research Council programs within endocrinology and he is a former president of Denmark’s National Academy of Technical Sciences. Until 2019 he chaired the governing board of the University of Copenhagen and he also currently serves on the board of Symphogen A/S, Denmark.

Dr. Thomas von Planta

Member
read more

Dr. Thomas von Planta

Member
« A combination of scientific, medical and financial expertise is needed to achieve successful investment results in the biotech sector»

Dr. Thomas von Planta has been elected Board member of BB Biotech AG in 2019. Since 2006, he is owner/director of CorFinAd AG – Corporate Finance Advisory (M&A transactions and capital market financings). Previously he worked for Vontobel Group from 2002–2006 as Head of Corporate Finance and member of the extended executive board. Prior to that he was with Goldman Sachs from 1992–2002, lastly in London in the Equity Capital Markets Group / Investment Banking Division. He holds a degree in law from the University of Basel and University of Geneva (Dr. iur.), attorney at law. He is a member of the Board of Directors of Bâloise Holding AG and a member of the advisory board of Harald Quandt Industriebeteili-gungen GmbH.